Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival

Authors: Chunxia Su, Caicun Zhou, Songwen Zhou, Jianfang Xu

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

To investigate whether expression of several cytokines affected clinical outcome in non-small cell lung cancer patients. A total of 86 stage IIIB/IV non-small cell lung cancer patients, treated with platinum-based doublets, were examined expression levels of IL-1, IL-2R, IL-5, IL-6, IFN-γ, TNF-α pre- and post-chemotherapy. Enzyme-linked immunosorbent assay technique was performed. Kaplan–Meier analysis and Cox regression analyses were used to adjust for possible confounding variables. IL-6 expression levels were significantly decreased due to chemotherapy in patients with stable disease (P = 0.041). IL-2R expression levels were significantly increased due to chemotherapy in patients with progression disease (P = 0.010). Patients with high concentrations of TNF post-chemotherapy had a significantly longer survival (P = 0.009, 17 months versus 11 months) than low levels. Multivariate analysis showed that sex, response rate, IL-1 and TNF-α were significantly predictive of the survival. Serum IL-6 and IL-2R levels correlated with chemoresponse in advanced non-small cell lung cancer, serum IL-1 and TNF-α can be predictive factors in advanced non-small cell lung cancer.
Literature
1.
go back to reference Camps C, Sirera R, Iranzo V, Tarón M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8(6):369–75.PubMedCrossRef Camps C, Sirera R, Iranzo V, Tarón M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8(6):369–75.PubMedCrossRef
2.
go back to reference Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16:2333–40.PubMedCrossRef Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16:2333–40.PubMedCrossRef
3.
go back to reference Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;1;10(15):4939–43.CrossRef Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;1;10(15):4939–43.CrossRef
4.
go back to reference Derin D, Soydinç HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in non-small cell lung cancer. Lung Cancer. 2008;59(2):240–5.PubMedCrossRef Derin D, Soydinç HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in non-small cell lung cancer. Lung Cancer. 2008;59(2):240–5.PubMedCrossRef
5.
go back to reference Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005;23(3):193–200.PubMedCrossRef Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005;23(3):193–200.PubMedCrossRef
6.
go back to reference Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006;24(5):492–6.PubMedCrossRef Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006;24(5):492–6.PubMedCrossRef
7.
go back to reference Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages ii and iii gastric carcinoma. Clin Cancer Res. 2008;15;14(2):428–34.CrossRef Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages ii and iii gastric carcinoma. Clin Cancer Res. 2008;15;14(2):428–34.CrossRef
8.
go back to reference Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004;49:246–51.PubMed Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004;49:246–51.PubMed
9.
go back to reference Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;5:1087–100. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;5:1087–100.
10.
go back to reference Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee S, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:292a. Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee S, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:292a.
11.
go back to reference Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285–91.PubMedCrossRef Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285–91.PubMedCrossRef
12.
go back to reference Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, et al. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non–small-cell lung cancer. Clinical Lung Cancer. 2008;9(Suppl. 2):S76–82.PubMedCrossRef Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, et al. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non–small-cell lung cancer. Clinical Lung Cancer. 2008;9(Suppl. 2):S76–82.PubMedCrossRef
13.
go back to reference Łukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5–6):247–51.PubMed Łukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5–6):247–51.PubMed
14.
go back to reference Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003;18;100(6):3410–5.CrossRef Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003;18;100(6):3410–5.CrossRef
15.
go back to reference Siemińska A. The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkur Lekarski. 2004;16(92):188–90.PubMed Siemińska A. The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkur Lekarski. 2004;16(92):188–90.PubMed
16.
go back to reference Song LH, Song XR, Liu MQ, Zhang XQ, Zheng L, Li XJ, et al. Prognostic factors in patients with stage III and IV non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2004;26(6):345–8.PubMed Song LH, Song XR, Liu MQ, Zhang XQ, Zheng L, Li XJ, et al. Prognostic factors in patients with stage III and IV non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2004;26(6):345–8.PubMed
Metadata
Title
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival
Authors
Chunxia Su
Caicun Zhou
Songwen Zhou
Jianfang Xu
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9645-6

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue